L-Carnitine Base vs L-Tartrate vs Acetyl-L-Carnitine
The decision in one line: Choose L-Carnitine Base for liquid formulations or maximum carnitine per gram; choose L-Carnitine L-Tartrate for solid dosage forms (tablets, capsules) needing stability; choose Acetyl-L-Carnitine (ALCAR) for cognitive health formulations specifically — it is the only form with meaningful independent evidence for neurological applications.
Quick Decision Guide
- L-Carnitine Base: Highest carnitine per gram, highly hygroscopic, best for liquid supplements
- L-Carnitine L-Tartrate: More stable, less hygroscopic, preferred for tablets/capsules
- Acetyl-L-Carnitine (ALCAR): Crosses blood-brain barrier more readily, specific cognitive/neuroprotective evidence, not interchangeable with the other two for cognitive applications
Side-by-Side Comparison
| L-Carnitine Base | L-Carnitine L-Tartrate | Acetyl-L-Carnitine (ALCAR) | |
|---|---|---|---|
| L-Carnitine content | ~100% | ~68% | ~68% (as carnitine equivalent) |
| Hygroscopicity | High — moisture-sensitive | Low — stable | Low |
| Best dosage form | Liquid, high-dose powder | Tablets, capsules | Tablets, capsules |
| Blood-brain barrier crossing | Limited | Limited | Yes — significantly better |
| Primary evidence | Fatty acid metabolism, energy | Fatty acid metabolism, exercise recovery | Cognitive function, neuroprotection |
| Sourcing (YNP) | China — confirmed catalogue SKU | China — confirmed catalogue SKU | China — confirm availability |
| Pack size | 25 kg drum | 25 kg drum | Confirm directly |
*(Table is horizontally scrollable on mobile)*
Evidence Summary by Form
L-Carnitine Base / L-Tartrate (shared evidence base for fatty acid metabolism): NIH confirms carnitine's biological role in mitochondrial fatty acid transport. Evidence for fat-loss effects in healthy individuals with adequate carnitine status is inconsistent (Section 32). L-Tartrate specifically has exercise recovery evidence (Stephens et al. 2006; Wall et al. 2011).
Acetyl-L-Carnitine — distinct neurological evidence: ALCAR has human trial evidence for cognitive applications that the other two forms lack. A meta-analysis by Montgomery et al. (2003) covering 21 controlled trials found ALCAR statistically superior to placebo in slowing cognitive decline, with effect sizes noted as modest and evidence described as preliminary. NIH ODS includes ALCAR in its carnitine fact sheet as a form with specific cognitive interest. This evidence does not transfer to L-Carnitine Base or Tartrate — they are different compounds with different brain penetration.
Frequently Asked Questions
Related Products
Related Buyer Guides
Related Glossary Terms
Related Downloads
References
Company Information
- YNP Ingredients, L-Carnitine product pages, ynpingredients.com
Industry Information
- NIH ODS. *Carnitine.* ods.od.nih.gov
- Stephens FB, et al. *An acute increase in skeletal muscle carnitine content alters fuel metabolism.* J Clin Endocrinol Metab. 2006;91(12):5013–5018.
- Montgomery SA, Thal LJ, Amrein R. *Meta-analysis of double blind randomized controlled clinical trials of acetyl-L-carnitine versus placebo.* Int Clin Psychopharmacol. 2003;18(2):61–71.